<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04940949</url>
  </required_header>
  <id_info>
    <org_study_id>18907A</org_study_id>
    <nct_id>NCT04940949</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Lu AF90103 in Healthy Men</brief_title>
  <official_title>Interventional, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study Part Investigating the Safety, Tolerability, and Pharmacokinetic and -Dynamic Properties of Lu AF90103 and a Double-Blind, Cross-Over Study Part Investigating the Safety Profile After Infusion of Lu AF90103 at Two Rates to Healthy Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and tolerability of Lu AF90103 and&#xD;
      what the body does to Lu AF90103 after single doses of the drug administered directly into a&#xD;
      vein.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is the first-in-human (FIH) study with Lu AF90103. The study is divided in two&#xD;
      parts, Part A and Part B.&#xD;
&#xD;
      Part A is an interventional, randomized, double-blind, sequential-group, placebo-controlled,&#xD;
      single-ascending dose study to investigate the safety, tolerability, pharmacokinetics, and&#xD;
      pharmacodynamics of Lu AF90103 in healthy men.&#xD;
&#xD;
      Part B is an interventional, randomized, double-blind, cross-over study to investigate the&#xD;
      safety profile after administration of Lu AF90103 as an infusion at two different rates to&#xD;
      healthy young men.&#xD;
&#xD;
      The dosage in Part B is guided by the cohorts in Part A and is a repetition of one of the&#xD;
      doses from Part A.&#xD;
&#xD;
      The total study duration per participant from baseline to the end of follow-up will be&#xD;
      maximum 11 days in Part A and 16 days in Part B.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2021</start_date>
  <completion_date type="Anticipated">August 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events</measure>
    <time_frame>From dosing (Day 1) to Day 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Lu AF90103 and AF88361 in Plasma and Cerebrospinal Fluid (CSF)</measure>
    <time_frame>0 (predose) up to 96 hours postdose on Day 1 to Day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Lu AF90103 and AF88361 in Plasma and CSF</measure>
    <time_frame>0 (predose) up to 96 hours postdose on Day 1 to Day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Clearance (CL) of Lu AF90103 and AF88361</measure>
    <time_frame>0 (predose) up to 96 hours postdose on Day 1 to Day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of Lu AF90103 and Lu AF88361 Excreted in Urine</measure>
    <time_frame>0 (predose) up to 96 hours postdose on Day 1 to Day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes to Time Matched Baseline in Area Under the Curve (AUC) of Medial Prefrontal (FZ and CZ Electrodes) High Frequency Gamma Signal (100-170 Hertz [HZ]) for Lu AF90103 at the Resting State</measure>
    <time_frame>From dosing (Day 1) to Day 4 (Part A) and Day 9 (Part B)</time_frame>
    <description>The AUC of medial prefrontal (FZ and CZ electrodes) high frequency gamma signal (100-170 HZ) will be derived for Lu AF90103 at resting state, as measured by electroencephalogram (EEG).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single Intravenous (IV) Dose of Lu AF90103</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single IV dose of Lu AF90103.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single IV Dose of Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single IV dose of placebo matching to Lu AF90103.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Single IV Doses of Lu AF90103</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 2 single IV doses of Lu AF90103 separated by at least 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF90103</intervention_name>
    <description>Lu AF90103 - powder for solution for infusion</description>
    <arm_group_label>2 Single IV Doses of Lu AF90103</arm_group_label>
    <arm_group_label>Single Intravenous (IV) Dose of Lu AF90103</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo - powder for solution for infusion</description>
    <arm_group_label>Single IV Dose of Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The participant is ≥18 and ≤45 years of age at the Screening Visit for Cohorts A1 to&#xD;
             A6 (excluding cohort A2b) or ≥55 to ≤65 for participants in the CSF sampling Cohorts&#xD;
             A2b and A7.&#xD;
&#xD;
          -  The participant has body mass index (BMI) ≥18.5 kilograms (kg)/square meter (m^2) and&#xD;
             ≤30 kg/m^2 and body weight ≥60 kilograms (kg) at the Screening Visit and at the&#xD;
             Baseline Visit.&#xD;
&#xD;
          -  The participant has a normal resting electroencephalogram (EEG) at Screening.&#xD;
&#xD;
          -  The participant is, in the opinion of the investigator, generally healthy based on&#xD;
             medical history, a physical examination, vital signs, an electrocardiogram (ECG), and&#xD;
             the results of the clinical chemistry, haematology, urinalysis, serology, and other&#xD;
             laboratory tests.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The participant has or has had any clinically significant immunological,&#xD;
             cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal,&#xD;
             endocrinological, haematological, dermatological, venereal, neurological, or&#xD;
             psychiatric disease or other major disorder.&#xD;
&#xD;
        Other inclusion and exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <phone>+45 36301311</phone>
    <email>LundbeckClinicalTrials@Lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>QPS Netherlands B.V.</name>
      <address>
        <city>GZ Groningen</city>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

